Feng Yan, Ge Qiong, Gao Jian, Wu Zhuoying, Zhang Yunyi, Mao Haiyan, Wu Beibei, Xu Changping
Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, China.
Molecules. 2025 Jan 17;30(2):387. doi: 10.3390/molecules30020387.
Despite the widespread use of COVID-19 vaccines, there is still a global need to find effective therapeutics to deal with the variants of SARS-CoV-2. (MH) is a herbal medicine credited with antiviral effects. This study aims to investigate the antiviral effects and the underlying mechanism of aqueous extract of (AEMH) for treating SARS-CoV-2. The in vitro anti-SARS-CoV-2 activity of AEMH was evaluated using cell viability and viral load. Component analysis was performed by HPLC-ESI-Q-TOF/MS. The connection between COVID-19 and AEMH was constructed by integrating network pharmacology and transcriptome profiles to seek the core targets. The components with antiviral activities were analyzed by molecular docking and in vitro pharmacological verification. AEMH exerted anti-SARS-CoV-2 effects by inhibiting viral replication and reducing cell death caused by infection (IC is 170 μg/mL for omicron strain). A total of 27 components were identified from AEMH. Through matching 119 intersection targets of 'disease and drug' with 1082 differentially expressed genes of COVID-19 patients, nine genes were screened. Of the nine, the PNP and TPI1 were identified as core targets as AEMH treatment significantly regulated the mRNA expression level of the two genes on infected cells. Three components, caffeic acid, luteolin, and rosmarinic acid, displayed antiviral activities in verification. Molecular docking also demonstrated they could form stable bonds with the core targets. This study explored the antiviral activity and possible mechanism of AEMH for treating SARS-CoV-2, which could provide basic data and reference for the clinical application of MH.
尽管新冠疫苗已广泛使用,但全球仍需要寻找有效的治疗方法来应对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的变种。(某草药名称,此处用MH指代)是一种具有抗病毒作用的草药。本研究旨在探讨某草药水提取物(AEMH)治疗SARS-CoV-2的抗病毒作用及其潜在机制。通过细胞活力和病毒载量评估AEMH的体外抗SARS-CoV-2活性。采用高效液相色谱-电喷雾电离-四极杆飞行时间质谱(HPLC-ESI-Q-TOF/MS)进行成分分析。通过整合网络药理学和转录组图谱构建新冠与AEMH之间的联系,以寻找核心靶点。通过分子对接和体外药理学验证分析具有抗病毒活性的成分。AEMH通过抑制病毒复制和减少感染引起的细胞死亡发挥抗SARS-CoV-2作用(奥密克戎毒株的半数抑制浓度为170μg/mL)。从AEMH中总共鉴定出27种成分。通过将“疾病与药物”的119个交集靶点与新冠患者的1082个差异表达基因进行匹配,筛选出9个基因。其中,嘌呤核苷磷酸化酶(PNP)和磷酸丙糖异构酶1(TPI1)被确定为核心靶点,因为AEMH处理显著调节了感染细胞上这两个基因的mRNA表达水平。三种成分,咖啡酸、木犀草素和迷迭香酸,在验证中显示出抗病毒活性。分子对接也表明它们可以与核心靶点形成稳定的键。本研究探索了AEMH治疗SARS-CoV-2的抗病毒活性及可能机制,可为某草药的临床应用提供基础数据和参考。